Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Clinical trial NCT02640209 · TERMINATED
Trial details
- NCT number
- NCT02640209
- Sponsor
- University of Pennsylvania
- Status
- TERMINATED
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-29
- Primary completion
- 2018-10-15
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.